NCT02449135No Longer Available不适用
Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma：Clinical Trial
Fuda Cancer Hospital, Guangzhou1 个研究点 分布在 1 个国家开始时间: 2015年5月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of nano drug interventional therapy using digital subtraction angiography（DSA） for pancreatic cancer. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
详细描述
By enrolling patients with pancreatic cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of nano drug interventional therapy using digital subtraction angiography（DSA）for pancreatic cancer.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Karnofsky performance status >60
- •Diagnosis of pancreatic cancer based on histology or the current accepted radiological measures.
- •Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ
- •Will receive interventional therapy
- •Life expectancy: Greater than 3 months
- •Patients' routine blood test, liver function and kidney function have no obvious abnormalities
- •Ability to understand the study protocol and a willingness to sign a written informed consent document
排除标准
- •Patients with other primary tumor except pancreatic cancer
- •History of coagulation disorders or anemia
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung CarcinomaLung CancerNCT02449122Fuda Cancer Hospital, Guangzhou60
已完成
1 期
Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver CarcinomaLiver CancerNCT02449109Fuda Cancer Hospital, Guangzhou60
已完成
3 期
Evaluation of the Efficacy and Safety of Nano-S1COVID-19 PneumoniaNCT05822180General Administration of Military Health, Tunisia116
已完成
1 期
Evaluation of NanoDoce® in Participants With Urothelial CarcinomaBladder CancerUrothelial CarcinomaUrinary Bladder NeoplasmUrinary Bladder CancerUrogenital NeoplasmsUrologic NeoplasmsUrologic CancerMalignant Tumor of the Urinary BladderCancer of the BladderNCT03636256NanOlogy, LLC36
已完成
不适用
Evaluate the Efficacy and Safety of the Digital Therapeutics Repeech for the Post-Stroke Dysarthria.Post-stroke DysarthriaNCT06670014HAII corp.ltd108